PE20140927A1 - Compuestos heterociclicos como inhibidores de cinasas - Google Patents

Compuestos heterociclicos como inhibidores de cinasas

Info

Publication number
PE20140927A1
PE20140927A1 PE2013002375A PE2013002375A PE20140927A1 PE 20140927 A1 PE20140927 A1 PE 20140927A1 PE 2013002375 A PE2013002375 A PE 2013002375A PE 2013002375 A PE2013002375 A PE 2013002375A PE 20140927 A1 PE20140927 A1 PE 20140927A1
Authority
PE
Peru
Prior art keywords
quinolin
amine
compounds
kinase
pirazolo
Prior art date
Application number
PE2013002375A
Other languages
English (en)
Inventor
Michael Almstetter
Michael Thormann
Andreas Tremil
Roland Koestler
Nasser Yehia
Original Assignee
Origenis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis Gmbh filed Critical Origenis Gmbh
Publication of PE20140927A1 publication Critical patent/PE20140927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE A ES O, S, C=O, ENTRE OTROS; Cy ES UN GRUPO ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R1 ES ALQUILO, ALQUENILO, ARILO, CICLOALQUILO, ENTRE OTROS; R2 ES H, HALOGENO, NO2, ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(m-TOLIL)-2H-PIRAZOLO[3,4-c]QUINOLIN-4-AMINA; N-(3-(TRIFLUOROMETIL)FENIL)-2H-PIRAZOLO[3,4-c]QUINOLIN-4-AMINA; N-(1H-INDAZOL-6-IL)-2H-PIRAZOLO[3,4-c]QUINOLIN-4-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS SYK (TIROSINA CINASA DE BAZO), LRRK2 (CINASA 2 DE REPETICION RICA EN LEUCINA) Y MYLK (CINASA DE LAS CADENAS LIGERAS DE MIOSINA) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS, AUTOINMUNES, NEURODEGENERATIVAS
PE2013002375A 2011-04-21 2012-04-23 Compuestos heterociclicos como inhibidores de cinasas PE20140927A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161517581P 2011-04-21 2011-04-21

Publications (1)

Publication Number Publication Date
PE20140927A1 true PE20140927A1 (es) 2014-08-24

Family

ID=46001141

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002375A PE20140927A1 (es) 2011-04-21 2012-04-23 Compuestos heterociclicos como inhibidores de cinasas

Country Status (25)

Country Link
US (1) US9499535B2 (es)
EP (1) EP2699572B1 (es)
JP (1) JP6278406B2 (es)
KR (1) KR101649610B1 (es)
CN (1) CN103717597B (es)
AP (1) AP2013007252A0 (es)
AU (1) AU2012244549B2 (es)
BR (1) BR112013026744B1 (es)
CA (1) CA2831680C (es)
CL (1) CL2013003052A1 (es)
CO (1) CO6831983A2 (es)
CR (1) CR20130537A (es)
CU (1) CU20130144A7 (es)
EA (1) EA034193B1 (es)
EC (1) ECSP13012984A (es)
GT (1) GT201300259A (es)
HK (1) HK1192247A1 (es)
IL (1) IL228967B (es)
MA (1) MA35123B1 (es)
MX (1) MX365784B (es)
PE (1) PE20140927A1 (es)
SG (1) SG194216A1 (es)
TN (1) TN2013000422A1 (es)
TW (1) TWI557121B (es)
WO (1) WO2012143143A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
AP2015008931A0 (en) 2011-04-21 2015-12-31 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014060113A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
EP2970333B1 (en) * 2013-03-15 2017-05-03 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
WO2015026683A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9801880B2 (en) * 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3302060B1 (en) * 2015-05-26 2020-02-12 Kaohsiung Medical University Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
AU2016322813B2 (en) * 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
CN105664178B (zh) * 2015-09-24 2019-08-20 洪健 Syk作为肝纤维化/硬化治疗靶点的应用
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190151B1 (ar) 2016-12-20 2023-09-17 Astrazeneca Ab مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
WO2018170199A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
BR112019027025A2 (pt) 2017-06-23 2020-06-30 Birdie Biopharmaceuticals, Inc. composições farmacêuticas
US11634416B2 (en) 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
JP2020132986A (ja) * 2019-02-25 2020-08-31 東京エレクトロン株式会社 成膜用組成物および成膜方法
CN111825694B (zh) * 2019-04-18 2023-08-11 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
US20220380373A1 (en) * 2019-09-13 2022-12-01 Origenis Gmbh 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease
DK4028017T3 (da) * 2019-09-13 2024-01-15 Origenis Gmbh 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme
WO2021101902A1 (en) * 2019-11-20 2021-05-27 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
WO2021207141A1 (en) * 2020-04-06 2021-10-14 The Regents Of The University Of Colorado, A Body Corporate METHODS OF USING NEUROKININ-1 RECEPTOR (NK-1R) ANTAGONISTS TO TREAT β-CORONAVIRUS INFECTION INCLUDING SARS-COV-2 INFECTION AND/OR COVID-19 DISEASE
BR112023000308A2 (pt) * 2020-07-06 2023-03-28 Acad Of Military Medical Sciences Uso de taurolidina contra vírus
WO2022079250A1 (en) * 2020-10-16 2022-04-21 Merck Patent Gmbh Compounds for the treatment of viral infections
CN112138015B (zh) * 2020-10-22 2022-08-05 合肥博思科创医药科技有限公司 三苄糖苷在治疗微循环障碍引起的皮肤疾病中的应用
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN116808016A (zh) * 2022-01-13 2023-09-29 浙江中医药大学 依普黄酮在抑制炎症小体活化中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3068673D1 (en) 1979-06-21 1984-08-30 Ciba Geigy Ag Pyrazolo-quinolines, processes for their production, and pharmaceutical compositions containing them
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546274A (en) * 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
WO2006107771A2 (en) * 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
US7943636B2 (en) * 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
PE20140407A1 (es) * 2008-06-10 2014-04-25 Abbott Lab Nuevos compuestos triciclicos
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
KR20110095857A (ko) * 2008-09-10 2011-08-25 칼립시스, 인코포레이티드 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제
JP2010143829A (ja) 2008-12-16 2010-07-01 Dainippon Sumitomo Pharma Co Ltd 新規なイミダゾキノリン誘導体
CN102428084B (zh) 2009-03-19 2016-05-18 医疗技术研究局 化合物
PE20130005A1 (es) 2009-12-01 2013-02-16 Abbvie Inc Compuestos triciclicos novedosos
TW201802091A (zh) 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
TW201204727A (en) 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors

Also Published As

Publication number Publication date
IL228967B (en) 2018-06-28
AU2012244549A1 (en) 2013-10-31
JP6278406B2 (ja) 2018-02-14
KR101649610B1 (ko) 2016-08-19
EA201301183A1 (ru) 2014-04-30
AU2012244549B2 (en) 2017-04-20
CA2831680A1 (en) 2012-10-26
CO6831983A2 (es) 2014-01-10
GT201300259A (es) 2016-07-07
IL228967A0 (en) 2013-12-31
MX365784B (es) 2019-05-28
MA35123B1 (fr) 2014-05-02
CN103717597A (zh) 2014-04-09
WO2012143143A1 (en) 2012-10-26
EP2699572B1 (en) 2016-08-10
US20120329785A1 (en) 2012-12-27
EP2699572A1 (en) 2014-02-26
CL2013003052A1 (es) 2014-05-23
BR112013026744A2 (es) 2017-01-03
HK1192247A1 (zh) 2014-08-15
CA2831680C (en) 2020-04-21
SG194216A1 (en) 2013-11-29
JP2014511884A (ja) 2014-05-19
AP2013007252A0 (en) 2013-11-30
US9499535B2 (en) 2016-11-22
TWI557121B (zh) 2016-11-11
BR112013026744B1 (pt) 2022-05-17
TW201247666A (en) 2012-12-01
MX2013012295A (es) 2014-03-27
EA034193B1 (ru) 2020-01-15
ECSP13012984A (es) 2014-09-30
CR20130537A (es) 2014-03-13
KR20140009495A (ko) 2014-01-22
CN103717597B (zh) 2017-07-04
TN2013000422A1 (en) 2015-03-30
CU20130144A7 (es) 2014-02-28

Similar Documents

Publication Publication Date Title
PE20140927A1 (es) Compuestos heterociclicos como inhibidores de cinasas
PE20140928A1 (es) Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
AR082154A1 (es) DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4
PE20161427A1 (es) Inhibidores heteroarilo de syk
EA201290073A1 (ru) Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
EA201001238A1 (ru) Соединения и композиции в качестве ингибиторов киназы
PE20151413A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
EA201270339A1 (ru) Замещенные производные ксантина
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20120110A1 (es) [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
EA201200218A1 (ru) Новые бициклические соединения мочевины
PE20130184A1 (es) Compuesto heterociclico

Legal Events

Date Code Title Description
FG Grant, registration